Key Points
- CEO Jason Coloma sold 34,501 Maze Therapeutics shares for approximately $907,000 at an average price of $26.29, reducing his stake by 65.53% to 18,151 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
- Maze’s shares opened at $25.87, with the stock trading between $14.16 and $53.65 over the past year. The company reported a quarterly loss of $0.76 per share, in line with analyst expectations, and analysts expect a full-year loss of $2.72 per share.
- Institutional ownership has increased through several major purchases, while analyst sentiment remains broadly positive: the stock carries a consensus “Buy” rating and a $66 average price target, despite some sell ratings.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 16,141 shares of the business's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $26.36, for a total value of $425,476.76. Following the sale, the chief marketing officer owned 16,141 shares in the company, valued at approximately $425,476.76. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Harold Bernstein also recently made the following trade(s):
- On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62.
- On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total transaction of $436,809.10.
Maze Therapeutics Stock Down 3.2%
NASDAQ:MAZE opened at $25.87 on Friday. Maze Therapeutics, Inc. has a one year low of $14.16 and a one year high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The company has a market cap of $1.44 billion, a PE ratio of -10.27 and a beta of 2.17. The firm's 50 day simple moving average is $28.74 and its 200 day simple moving average is $31.20.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). On average, research analysts anticipate that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on MAZE shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Finally, BTIG Research reissued a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Maze Therapeutics presently has an average rating of "Buy" and an average target price of $66.00.
Check Out Our Latest Stock Report on MAZE
Institutional Trading of Maze Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada lifted its holdings in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after acquiring an additional 363 shares during the period. Ameritas Investment Partners Inc. grew its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after purchasing an additional 738 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics in the 4th quarter valued at $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $48,000. Finally, Russell Investments Group Ltd. increased its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after purchasing an additional 1,725 shares during the last quarter.
Maze Therapeutics Company Profile
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
